Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RITCOLON: TF2 + 90Y-IMP288 in Metastatic Colorectal Cancer
NCT02300922Phase 2Terminated
- Sponsor
- CHU de Nantes
- Start
- Jan 2015
- Primary completion
- Sep 2017
- Modality
- Bispecific Antibodies, Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of hMN-14 × m734, 90-Y-IMP-288 in metastatic colorectal cancer (mCRC), sponsored by CHU de Nantes. Started Jan 2015; status: terminated.
02
Drugs
hMN-14 × m73490-Y-IMP-288
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02300922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02300922.